Recall for U.S. Only

Country Sites

Search

Recall for U.S. Only

Country Sites

Press Releases

Dec

Dr. Reddy's Laboratories announces the launch of Nystatin and Triamcinolone Acetonide Cream, USP in the U.S. Market

Nov

Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market

Oct

Dr. Reddy's Laboratories announces new strategic deal with Gland Pharma in the U.S. Market
Dr. Reddy’s Q2 and H1 FY17 Financial Results
Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets, USP tablets in the U.S. Market
Leading global pharmaceutical company, Dr. Reddy’s Laboratories now in Colombia
Dr. Reddy's Laboratories announces the launch of Lamotrigine Orally Disintegrating Tablets in the U.S. Market

Sep

Aug

Jul

Jun

May

Apr

ZEMBRACE^TMSymTouch^TM(sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.

Mar

Feb

Jan

Dr. Reddy’s Laboratories Ltd. Receives FDA approval for ZEMBRACETMSymTouchTM (sumatriptan succinate) Injection for the acute treatment of migraines in adults